Bachanova V, Weisdorf D
Department of Medicine, University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA.
Bone Marrow Transplant. 2008 Mar;41(5):455-64. doi: 10.1038/sj.bmt.1705889. Epub 2007 Oct 29.
Acute lymphoblastic leukemia is highly sensitive to induction chemotherapy; however, long-term survival in adults has been less than 35%, primarily as a result of high relapse rate. Treatment for relapsed disease is even less successful. The optimal post-remission therapy in the first complete remission offers the best opportunity for leukemia-free survival. Allogeneic donor stem cell transplantation can offer a unique anti-leukemia effect and a potential for extended survival. We will discuss advances in unrelated donor (URD) stem cells transplantation, improvements in transplantation process and supportive care along with growing experience with umbilical cord blood (UCB) allografts.
急性淋巴细胞白血病对诱导化疗高度敏感;然而,成人的长期生存率一直低于35%,主要原因是复发率高。复发性疾病的治疗甚至更不成功。首次完全缓解后的最佳缓解后治疗为无白血病生存提供了最佳机会。异基因供体干细胞移植可提供独特的抗白血病作用和延长生存的潜力。我们将讨论无关供体(URD)干细胞移植的进展、移植过程的改进和支持治疗,以及脐血(UCB)同种异体移植的经验积累。